drugset / Trial / NCT01587352
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Phase 2
Active not recruiting
40 enrolled
National Cancer Institute (NCI)
Institut Curie Paris · collabMemorial Sloan Kettering Cancer Center · collabMoffitt Cancer Center P2C · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2012-05-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | — | Oral |